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Abstract
Fibrillin-1 is the major component of the 10–12 nm diameter extracellular matrix microfibrils. The majority of mutations
affecting thehumanfibrillin-1 gene, FBN1, result inMarfan syndrome (MFS), a commonconnective tissuedisorder characterised
by tall stature, ocular and cardiovascular defects. Recently, stiff skin syndrome (SSS) and a group of syndromes known
collectively as the acromelic dysplasias, which typically result in short stature, skin thickening and joint stiffness, have been
linked to FBN1mutations that affect specific domains of the fibrillin-1 protein. Despite their apparent phenotypic differences,
dysregulation of transforming growth factor β (TGFβ) is a common factor in all of these disorders. Using a newly developed assay
to track the secretion and incorporation of full-length, GFP-tagged fibrillin-1 into the extracellular matrix, we investigated
whether or not there were differences in the secretion and microfibril assembly profiles of fibrillin-1 variants containing
substitutions associated with MFS, SSS or the acromelic dysplasias. We show that substitutions in fibrillin-1 domains TB4 and
TB5 that cause SSS and the acromelic dysplasias do not prevent fibrillin-1 from being secreted or assembled into microfibrils,
whereas MFS-associated substitutions in these domains result in a loss of recombinant protein in the culture medium and no
association with microfibrils. These results suggest fundamental differences in the dominant pathogenic mechanisms
underlying MFS, SSS and the acromelic dysplasias, which give rise to TGFβ dysregulation associated with these diseases.
Introduction
Human fibrillin-1 is a 350 kDa glycoprotein that constitutes the
major structural component of the 10-12 nm diameter extra-
cellular microfibrils of metazoan species. In addition to confer-
ring structural support to tissues and providing a scaffold for
the deposition of elastin during elastogenesis (1–3), fibrillin mi-
crofibrils are involved in multiple interactions with cells and
other connective tissue components that function to regulate
the production of extracellular matrix. These include the binding
of cells to fibrillin-1 via the integrins αvβ3, α5β1 and αvβ6 (4–6),
and the sequestration on microfibrils of growth factors such as
transforming growth factor-β (TGFβ) and the bone morphogenetic
proteins (BMPs) (7–9).
The structure of fibrillin-1 is dominated by 43 calcium-
binding epidermal growth factor-like (cbEGF) domains inter-
spersed with 7 transforming growth factor β-binding protein-like
(TB) domains (Fig. 1A). TB domains are found only in the fibril-
lin/LTBP superfamily of proteins (11). Their structure is charac-
terised by eight cysteine residues, disulphide bonded in a C1-C3,
C2-C6, C4-C7, C5-C8 arrangement, with a small hydrophobic core
that in most cases is formed by a conserved tryptophan (6,12,13).
The majority of mutations affecting the gene encoding human fi-
brillin-1, FBN1, result in Marfan syndrome (MFS), a common
(1:5000 incidence), autosomal dominant disorder of the fibrous
connective tissue with highly variable clinical manifestations
characterised by skeletal, ocular and cardiovascular defects.
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MFS-associated mutations affect all domains of fibrillin-1 and,
until recently, fewgenotype–phenotype correlationshave been es-
tablished. An exception was the ‘neonatal’ region, spanning from
domains cbEGF11-18, which is associated with a severe, early
onset form of MFS (14).
Although the vast majority of FBN1mutations lead to MFS, in
the past decade a series of disorders with phenotypes that con-
trast strongly with those observed in MFS have been linked to
mutations affecting specific domains of fibrillin-1. Loeys et al.
(15) identified three substitutions (C1564S, W1570C and C1577G)
linked to stiff skin syndrome (SSS) and a further substitution
(G1594N) linked to a hybrid syndrome featuring stiff skinwith ec-
topia lentis. All of these result from mutations affecting domain
TB4 of fibrillin-1 (Fig. 1B), which contains the only integrin-
binding RGD motif of the molecule. In contrast to MFS, SSS is a
congenital form of scleroderma characterised by the develop-
ment of hard, thickened skin over most of the body, without
the typical skeletal, ocular and cardiovascular features of MFS.
In addition to SSS, several mutations affecting fibrillin-1 have
been linked to another series of disorders, known collectively
as the acromelic dysplasias (Fig. 1C). These syndromes, which
include geleophysic dysplasia, acromicric dysplasia and Weill–
Marchesani syndrome, are characterised by short stature, short
extremities and joint stiffness, with skin thickening also present
in some cases. At present, 16 missense mutations and an amino
acid duplication, all affecting domain TB5, are known to result in
either geleophysic dysplasia or acromicric dysplasia (16,17).
Fibrillin-associated mutations causing the dominant form of
Weill–Marchesani syndrome include two substitutions (R1596P
and C1748R) and an eight amino acid deletion affecting domain
TB5 (18–20), a substitution (G214S) in the first hybrid domain
(21) and a deletion of exons 9–11 resulting in the loss of domains
TB1 to EGF4 (19). Despite the phenotypic differences between
SSS, the acromelic dysplasias and MFS, dysregulation of TGFβ is
a prominent feature in all of these disorders (22).
Previous studies on the pathogenesis of MFS have examined
the effects of mutations on aspects of the fibrillin-1 biosynthetic
pathway including transcription (23,24), post-translationalmodi-
fication (25–27), susceptibility to degradation by proteases (28–31)
and trafficking (25,32–34). Pulse chase studies of MFS patient
fibroblasts with missense mutations in FBN1 have shown three
different cellular phenotypes of normal secretion, delayed secre-
tion/ retention, and happloinsufficiency of fibrillin-1. In studies
of a series of MFS-associated substitutions in cbEGF domains,
Figure 1. Fibrillin-1 domain organisation and mutation sites in domains TB4 and TB5. (A) The fibrillin-1 domain organisation is dominated by calcium-binding EGF-like
domains (white) interspersed with transforming growth factor β-binding protein-like (TB; blue) and hybrid (diagonal stripes) domains. Other regions include the fibrillin
unique N-terminal (FUN; purple) and non-calcium-binding EGF-like (grey) domains, a proline-rich region (orange) and a conserved 2Cys domain (yellow). N- and C-
terminal propeptides (black) are processed by furin before microfibril assembly. (B) Structure of the cbEGF22-TB4-cbEGF23 fragment of fibrillin-1 (pdb 1UZJ) (6), with
RGD integrin binding site indicated, showing the sites affected by SSS substitutions C1564S and W1570C (cyan spheres, left panel) and MFS substitution C1564Y
(magenta spheres, right panel). In essence, residues important for stabilising TB domain fold are affected. (C) Homology model of the cbEGF24-TB5-cbEGF25 region of
fibrillin-1, showing sites affected by geleophysic and acromicric dysplasias (light orange and dark orange spheres, respectively, left panel) and MFS substitutions
(magenta spheres, right panel). All are predicted to affect the fold of the domain. The cbEGF24-TB5-cbEGF25 model was created with Modeller software using the
cbEGF22-TB4-cbEGF23 structure as a template (10). Figures were rendered using PyMOL (Schrödinger, LLC) to show cbEGF domains (green), TB domains (blue), calcium
ions (red) and disulphide bonds (yellow).
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both secreted and retained mutant proteins were described
(32,33). Recently methods have become available to track the
fate of specific fibrillin-1mutant proteins into the assemblingmi-
crofibrils (35,36) and have allowed the role of the C-terminal pro-
peptide to be identified. The range of effects that have been
observed to date suggest that all aspects of themicrofibril biosyn-
thetic pathway, from fibrillin-1 transcription to secretion, assem-
bly and interactions at the cell surface, need to be investigated to
understand disease pathogenesis. This will be especially import-
ant in disentangling the different pathogenic mechanisms lead-
ing to MFS, SSS and the acromelic dysplasias. Understanding
these processes will provide new insights into how microfibrils
influence integrin signalling and regulate growth factors such
as TGFβ and the BMPs in the extracellular matrix.
In this study, we used a GFP-tagged version of full-length fi-
brillin-1 (36) and an established fibroblast secretion assay (32)
to follow the secretion and microfibril incorporation of a series
of fibrillin-1 TB domain mutants associated with MFS, SSS and
acromelic dysplasias. We show that MFS-associated substitu-
tions affecting domains TB4 and TB5 lead to a loss of fibrillin-1
from the cell culture medium whereas mutants associated with
SSS and the acromelic dysplasias are secreted and detected in
the extracellular media. The SSS and acromelic dysplasia-asso-
ciatedmutantswere further shown to incorporate into themicro-
fibril network produced by fibroblasts in culture. These data
support amodel inwhich SSS and the acromelic dysplasias result
from changes in microfibril interactions post-assembly, rather
than a loss of microfibrils as in MFS, and suggest important dif-
ferences in the mechanisms leading to TGFβ dysregulation in
these diseases.
Results
Fibrillin-1 domain TB4 SSS mutants are secreted and
incorporate into microfibrils
In a previous study using a fibrillin-1 mini-gene construct, we
showed that the SSS-associated substitutions C1564S and
W1570C in domain TB4 do not abrogate secretion of fibrillin-1
from fibroblasts (15). In this study, we compared the cell traffick-
ing profiles of SSS substitutions C1564S and W1570C with a
C1564Y substitution in domain TB4 associated with MFS (Fig. 1),
in the context of a full-length GFP-tagged fibrillin-1 construct.
Consistent with the fibrillin-1 mini-gene data, the GFP-Fbn con-
structs containing the SSS-associated substitutions C1564S and
W1570Cwere detected inmedium samples from cultures of tran-
siently transfectedHEK293T cells (Fig. 2). In contrast, the GFP-Fbn
construct harbouring the MFS-associated substitution C1564Y
was not detected in medium samples despite the recombinant
protein being detected in cell fractions, suggesting either intra-
cellular retention or a rapid turnover of the recombinant protein
in the culture medium. Semi-quantitative RT–PCR analysis
showed that the levels of recombinant transcript were similar
in cells transfected with either the wild-type GFP-Fbn or
C1564Y mutant (Supplementary Material, Fig. S1), indicating
that the lack of recombinant protein observed in the medium in
the C1564Y samples was not due to a lack of transcript.
To assess the ability of fibrillin-1 molecules containing the
SSS-associated substitutions to incorporate into microfibrils in
culture, we used a microfibril incorporation assay (36) in which
HEK293T cells transiently expressing wild-type GFP-Fbn (WT),
GFP-FbnC1564S or GFP-FbnW1570C (Fig. 3, Panels A–C) were
co-cultured with human dermal fibroblasts. As in the case of
the wild-type recombinant protein, the GFP-Fbn variants
containing theC1564SorW1570Csubstitutionswereable to incorp-
orate into the fibrillin-1 microfibril network. No GFP-tagged micro-
fibrils were observed in cultures expressing the C1564Y construct
(Fig. 3J), as expected by the lack of recombinant protein observed
in medium samples from transiently transfected HEK293T cells.
These data suggest that the C1564S- and W1570C-substituted
fibrillin-1 mutants are not defective in their capacity to incorpor-
ate into microfibrils.
Fibrillin-1 domain TB5 geleophysic dysplasia and
acromicric dysplasia mutants are secreted and
incorporate into microfibrils
When expressed in HEK293T cells, GFP-Fbn fusions with either
geleophysic dysplasia or acromicric dysplasia-associated substi-
tutions in TB5 were secreted into the culture medium (Fig. 2). In
contrast, the MFS-associated substitutions C1719Y and C1720Y
resulted in a lack of detectable protein in the media, suggesting
Figure 2. Secretion profiles of GFP-Fbn constructs with disease-associated substitutions. Mutations associated with MFS, SSS, geleophysic dysplasia (GD) or acromicric
dysplasia (AD) in domains TB4 and TB5 were engineered into a GFP-tagged fibrillin-1 construct (36) and the resulting constructs used to transiently transfect HEK293T
cells. After 3 days in culture, samples of the medium and cell lysates were analysed by western blotting following separation on a reducing 6% SDS-PAGE gel, using an
anti-GFPantibody. SSS, GD andADmutantsweredetected in the culturemedium, in contrast to theMFSmutants. Empty vector (pcDNA) and thewild-type construct (GFP-
Fbn)wereused as negative andpositive controls. Cell lysate samples showed that the lackof recombinantmaterial in themedia of theMFSmutantswas not due to a loss of
protein expression.
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either intracellular retention or an increased rate of turnoveras in
the case of the MFS-associated TB4 domain mutant, C1564Y.
Semi-quantitative RT–PCR was carried out on RNA samples
from cultures of HEK293T cells transfected with either the wild-
type or MFS-associated GFP-Fbn constructs to ensure that the
lack of secretion was not due to a lack of recombinant transcript
(Supplementary Material, Fig. S1).
Using the GFP-Fbn microfibril binding assay, we found that
the GFP-Fbn constructs containing substitutions associated
with either geleophysic dysplasia (Fig. 3, Panels D–F) or acromic-
ric dysplasia (Fig. 3, Panels G–I) showed incorporation into the
fibroblast-derived microfibril network to a similar level as that
seen for wild-type GFP-Fbn. As in the case of the TB4 domain
C1564YMFS-associatedmutant, none of the TB5 domainMFS-as-
sociated GFP-Fbn constructs were detected in themicrofibril net-
work assembled by the FS2 fibroblasts in co-culture (Fig. 3, Panels
K and L), consistentwith the lackof secretedmaterial observed by
western blotting of medium samples. Staining of the cultures
using an antibody against the fibrillin-1 proline-rich region
showed that themicrofibril network assembled by the fibroblasts
in the co-cultures was not affected by the presence of the
HEK293T cells expressing any of the disease-associated mutants
(Supplementary Material, Fig. S2). These data indicate that the
mutations associated with geleophysic dysplasia and acromicric
dysplasia do not lead to an obvious change in the ability of fibril-
lin-1 monomers to assemble into microfibrils.
Figure 3.Microfibril incorporation ofmutant GFP-Fbn constructs. FS2 fibroblasts were co-cultured for 5 dayswith HEK293T cells transiently transfected to express GFP-Fbn
(WT; Panel A) or GFP-Fbn variants associated with SSS (Panels B and C), geleophysic dysplasia (GD; Panels D–F), acromicric dysplasia (AD; Panels G–I) or MFS (Panels J–L).
Co-cultures were then fixed and stained using an anti-GFP antibody as described previously (36). SSS-associatedmutants C1564S andW1570C, as well as the geleophysic
dysplasia and acromicric dysplasia mutants, produced recombinant microfibril networks that were indistinguishable from thewild type. Co-cultures expressing the MFS
mutants showed no recombinant microfibril staining, consistent with the lack of recombinant material observed in medium samples by western blotting (Fig. 2).
Bar = 100 μm. Staining for endogenous fibrillin-1, expressed by the FS2 cells, is shown in Supplementary Material, Figure S2.
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Secretion profiles of fibrillin-1 domain TB4 MFS and SSS
mutants from fibroblasts
To assess the effects of these substitutions on protein secretion
from a microfibril-assembling cell line rather than HEK293T
cells, which are epithelial in origin and do not assemble microfi-
brils, we used a previously described assay (32) in which pools of
stably transfected clones of the human fibroblast cell line, MSU-
1.1, are created to express a fibrillin-1 mini-gene (Fig. 4). MSU-1.1
fibroblasts are able to assemble extracellular microfibrils and con-
tain all the cellular factors required for fibrillin-1 folding, process-
ing, secretion and assembly (37). Pools of clones expressing the
NPro-cbEGF18–26 fibrillin-1 mini-gene (Fig. 4A) were assayed to
average out any variation in transgene expression levels caused
by random genomic integration. Conditioned medium from
pools of MSU-1.1 clones obtained after transfection with NPro-
cbEGF18-26 wild-type, W1570C, C1564S or C1564Y constructs
were analysed by western blotting using an antibody raised
against the proline-rich region of fibrillin-1 (Fig. 4B). In medium
samples fromwild type,W1570C andC1564S pools, the recombin-
ant NPro-cbEGF18-26 fragment, which migrates at ∼150 kD, was
always detected in themedium. This bandwas absent inmedium
samples from untransfected MSU-1.1 cells, confirming that it is
derived from the recombinant construct. In contrast, medium
samples of pools expressing the C1564Y-substituted protein
showed the presence of endogenousfibrillin-1 but greatly reduced
the levels of the recombinant protein comparedwith thewild type
and SSS forms. In addition, little C1564Y-substituted fusion was
detected in the cell fraction, suggesting either a lack of expression
or increased rate of turnover. Semi-quantitative RT–PCR analysis
showed that the recombinant constructs were expressed at simi-
lar levels at themRNA level (SupplementaryMaterial, Fig. S3). The
results suggest that the MFS-causing mutation C1564Y in domain
TB4 results in a reduction in the amount of fibrillin-1 secreted by
fibroblasts, consistent with the HEK293T data and in contrast to
the SSS-causingmutants in domain TB4, which are secreted at le-
vels comparable to the wild type.
Secretion profiles of fibrillin-1 domain TB5 MFS and
acromelic dysplasia mutants from fibroblasts
Although the majority of known missense mutations that affect
fibrillin-1 domain TB5 result in the development of acromelic
dysplasias (16), missense mutations associated with MFS have
also been described (21,38,39). Using the fibroblast secretion
Figure 4. Construction of the NterPro-cbEGF18-26 fibrillin-1 fragments and fibroblast secretion assays. (A) NterPro-cbEGF18-26 is a fusion of the N-terminal region of
fibrillin-1, up to the proline-rich domain (orange), with the cbEGF18-26 region, which encompasses domains TB4 and TB5. The smaller size of this construct allows it
to be distinguished from full-length fibrillin-1, following reducing SDS-PAGE, in western blots of medium from stably transfected fibroblasts when developed with an
antibody raised again the proline-rich domain. (B) Secretion profiles of TB4 and TB5 domain-mutant constructs associated with MFS, SSS, acromicric dysplasia (AD) or
geleophysic dysplasia (GD).Mediumand cell lysate samples fromuntransfectedfibroblasts (MSU-1.1) and fibroblasts transfectedwith thewild-type control construct (WT)
were run as controls, allowing the identification of the recombinant construct (fusion). The full-length fibrillin-1 band (Fbn-1) acts as an endogenously expressed loading
control. In cell lysates, a band migrating at ∼230 kDa (*) is likely to be due to a degradation product of the endogenously expressed fibrillin-1.
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assay and the NterPro-cbEGF18-26 construct, we compared the
secretion profiles (Fig. 2) of two MFS-associated missense mu-
tants (C1719Y and C1720Y) with the secretion profiles of mutants
associated with geleophysic dysplasia (Y1699D, C1719W and
G1762S) and acromicric dysplasia (Y1700C, S1722C and D1758V).
Themutant fusion proteinswith acromicric dysplasia-associated
substitutions (AD) were mainly secreted into the medium, with
little evidence of material being retained in the cells. In the
case of geleophysic dysplasia-associated substitutions (GD), the
Y1699D and G1762S variants were detected in the medium
whereas the C1719W form was also found at increased levels in
cell lysates, suggesting partial retention in this case. In contrast,
only trace amounts of the MFS-associated substitutions C1719Y
and C1720Y were detected in medium samples, with increased
levels of the fusion protein retained within the cells. In all
cases, semi-quantitative RT–PCR analysis was carried out using
RNA extracted from all pools of clones to ensure that differences
in secretion profiles were not due to the differences in the levels
of transcript expression (Supplementary Material, Fig. S3). These
data suggest that the MFS-associated TB5 domain substitutions
studied here cause fibrillin-1 to be intracellularly retainedwhere-
as the acromelic dysplasia-associated TB5 domain mutants
have secretion profiles similar to the wild type, except in the
case of C1719W where there is also some intracellular retention
detected.
Discussion
We have investigated the effects on secretion and microfibril as-
sembly of a series of substitutions in fibrillin-1 domains TB4 and
TB5 that have been linked to syndromes with markedly different
phenotypes. Themutants studied affected various parts of theTB
domain structure, including an N-terminal loop adjacent to the
C2-C6 disulphide bond (Y1699D and Y1700C), the hydrophobic
core region (C1564S, C1564Y, W1570C, C1719Y, C1719W and
S1722C) and the C-terminal β-sheet (D1758V and G1762S).
While the substitutions outside of the hydrophobic core region
were found to have little effect on protein secretion, there were
mixed results from substitutions near the core of the domain.
In the cases of residues C1564 and C1719, we observed opposing
effects with different substitutions. In both cases, substitution of
the cysteine residue with a tyrosine resulted in a loss of recom-
binant protein in the cell culture medium. The SSS-associated
substitution, C1564S, was similar to wild type in terms of secre-
tion and microfibril binding. It could be reasoned that this
change, while causing the loss of a conserved disulphide, may
lead to only localised misfolding because cysteine and serine
are similar in size. The C1719Wgeleophysic dysplasia-associated
substitution is of particular interest because its effects on secre-
tion and microfibril assembly are different to those observed for
the MFS-associated C1719Y substitution, even though in both
cases cysteine is replaced with an aromatic residue. Apart from
the difference in size between tryptophan and tyrosine side
chains, an obvious difference is the presence of a hydroxyl
group on tyrosine, whichmay lead to the formation of disruptive
hydrogen bonds within the domain structure. Substitutions
C1564Y and C1720Y, which are also associated with MFS, also re-
sult in a loss of protein in the medium, suggesting that tyrosine
residues in these positions lead to more severe misfolding.
SSS-causing amino acid substitutions C1564S andW1570C af-
fect structurally important residues of domain TB4 (Fig. 1B),
which is the only domain within fibrillin-1 containing an integ-
rin-binding RGDmotif. The secretion of these mutant molecules
is interesting considering that these substitutions, by definition,
will result in misfolding. A tryptophan is found in the position
corresponding to residueW1570 in almost all known TB domains
of the fibrillins and LTBPs and is involved in forming the hydro-
phobic core of the domain (6,12,13). Residue C1564 is involved
in forming one of the four conserved disulphide bonds that define
the structure of the TB domain.
As in the case of the SSS mutants in domain TB4, the substi-
tutions in domain TB5 associated with the acromelic dysplasias
did not abolish secretion of either the GFP-Fbn construct from
HEK293T cells or the NterPro-cbEGF18-26 construct from fibro-
blasts. Only the C1719W substitution, associated with geleophy-
sic dysplasia, showed a degree of intracellular retention in the
fibroblast system. Of the two acromelic dysplasias studied here,
geleophysic dysplasia has the more severe phenotype with car-
diovascular involvement (22). Apart from the partial intracellular
retention we observed for the C1719W substitution, our data do
not provide a clear explanation for the difference in disease
phenotype. Some substitutions have been linked to both geleo-
physic dysplasia and acromicric dysplasia (16), suggesting that
these diseases may form a spectrum of severity influenced by
other modifying factors.
In previous studies on the secretion profiles of fibrillin-1
cbEGF domain mutants associated with MFS or the more severe
neonatal form of MFS (32,33), no clear correlations were observed
between disease severity and protein secretion. In the present
study, the MFS-associated substitutions in domains TB4 and
TB5 resulted in a loss of recombinant protein in the tissue culture
medium, presumably due to intracellular retention. An increased
susceptibility to extracellular protease digestion, however, can-
not be excluded. Further analysis of other MFS-associated substi-
tutions would be required to determine whether the apparent
lack of secretion we observed is a common feature of mutations
that affect TB domains.
The microfibril incorporation data presented suggest that the
SSS-associated mutants are still able to assemble and incorpor-
ate into the matrix, although interactions with integrins may
be disrupted owing to altered solvent accessibility or presenta-
tion of the RGD loop. This is consistent with previouswork show-
ing that the replacement of the RGD integrin-binding motif with
an RGA sequence does not disrupt microfibril assembly (35). Our
data suggest that cell–matrix interactions between integrins and
microfibrils, downstreamofmicrofibril assembly,must be altered
in SSS. This would be consistent with the data from a mouse
model of SSS obtained by Gerber et al. (40) who showed that der-
mal fibrosis in mutant animals could be reversed by integrin-
modulating therapies. SSS substitutions C1564S and W1570C
were previously shown to induce a loss of attachment and
spreading of fibroblasts plated onto fibrillin-1 fragments contain-
ing domain TB4 (cbEGF22-TB4-cbEGF23), indicating an impaired
interaction of these fragments via the RGD motif with the integ-
rin αvβ3 (15). This suggests that the structural consequences of
the C1564S andW1570Cmutations extend to the RGD loop of do-
main TB4 either through short-range effects limited to the TB do-
main or by disruption of the extensive hydrophobic interfaces
that occur between domain TB4 and the adjacent cbEGF domains
(6,41). The interactionwith integrin αvβ6was still viable however,
suggesting that the RGDmotif could still bind to a smaller reper-
toire of integrins.
Domain TB5 has been implicated as a region on fibrillin-1 in-
volved in binding to heparan sulphate proteoglycans (HSPGs)
(42). A 24-bp in-frame deletion in domain TB5 linked to Weill–
Marchesani syndrome and missense mutants linked to the ge-
leophysic and acromicric dysplasias have been reported to alter
the interactions of this region of fibrillin-1 with heparan sulphate
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(43). Although there is substantial evidence for the role of cell-
surface HSPGs in the assembly of fibrillin microfibrils (42,44–46),
a specific interaction between a cell-surface HSPG and fibrillin-1
is still to be demonstrated biochemically. In marked contrast to
the TB5 domain MFS mutants, all of the acromelic dysplasia-as-
sociated mutants we investigated were able to associate with
fibroblast-derived microfibrils in the GFP-Fbn co-culture assay.
This suggests that, as in the case of the SSSmutants, the acrome-
lic dysplasia mutants may be acting at the level of cell–matrix in-
teractions rather than disrupting microfibril assembly and that
heparan sulphate interactions involving this region of fibrillin-1
are not critical for assembly. Bax et al. (47) showed that heparan
sulphate-binding modulates integrin binding to the TB4 domain
of fibrillin-1. Integrin and cell-surface HSPGs could interact in
concert to regulate signalling on binding to microfibrils. Synde-
cans, which are a group of cell-surface proteoglycans, are able
to modulate integrin signalling at focal adhesions (48) and are a
potential binding partner for the fibrillin-1 TB5 domain. Disrup-
tion of either the integrin or HSPG interaction may alter cellular
responses, leading to changes in the expression levels of other
matrix components or growth factors, and ultimately lead to
the development of either SSS or an acromelic dysplasia.
The role of TGFβ in the pathogenesis of MFS was initially de-
monstrated by Neptune et al. (49) in a mouse model, and current
data from both patient samples and animal models suggest that
the fibrosis observed in SSS and the acromelic dysplasias is also
due to TGFβ dysregulation (15,50,51). Themechanisms leading to
TGFβ dysregulation, and how they result in the different pheno-
types observed in these syndromes, remains unclear. Our data
show that MFS-associated substitutions in domains TB4 and
TB5 reduce the concentration of fibrillin-1 found in the medium
of cultured cells, with a corresponding lack of mutant protein
being incorporated into microfibrils. This is consistent with a
dominant mechanism in which a functional haploinsufficiency
of fibrillin-1 or loss of microfibrils is at the heart of the pathogen-
esis ofMFS, as shown bymousemodels and human deletionmu-
tants (52,53). Based on the ability of the non-MFS TB domain
mutants presented here to secrete and be incorporated into mi-
crofibrils, we propose that the phenotypes of SSS and the acrome-
lic dysplasias are not caused by a primary defect in microfibril
Figure 5.Model of themechanisms leading to different dominantly inherited fibrillinopathies associated with fibrillin-1 domains TB4 and TB5. (A) Wild-type fibrillin-1 is
secreted from cells and assembled to produce amicrofibril network that influences cell signalling through integrins and cell-surface HSPGs. Normal matrix deposition of
growth factors (green and yellow), and growth factor activation, is mediated by interactions between cells and microfibrils (curved arrows). (B) When one of the alleles
carries a pathogenic mutation that results in intracellular retention of the mutant protein, fewer functional microfibrils are produced in all tissues. Altered tissue
dynamics, and possibly a reduction in growth factor binding sites in the matrix, lead to a general increase in growth factor activation and the development of MFS,
but with microfibrils maintaining normal interactions with integrins and cell-surface HSPGs. (C) Alternatively, the mutant proteins could be secreted and assembled
into structurally normal microfibrils, with defective interactions between microfibrils and integrins and/or cell-surface HSPGs being affected by altered binding site
presentation. The resulting alterations in signalling lead to a secondary upregulation in the production of extracellular matrix. In these cases, the resulting phenotype
is limited to tissues expressing the cell-surface proteins most sensitive to the altered binding sites on the microfibril, as seen in SSS and the acromelic dysplasias.
4460 | Human Molecular Genetics, 2015, Vol. 24, No. 15
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/24/15/4454/2453040 by Jam
es C
ook U
niversity user on 18 D
ecem
ber 2019
assembly. Instead, thesemutants aremore likely to alter the cell–
matrix interactions involving microfibrils (Fig. 5) leading to sec-
ondary effects on the extracellular matrix, such as fibrosis. The
types of alterations would depend on the repertoire of cell-sur-
face proteins in particular tissues and would explain the more
limited range of tissues affected in SSS and the acromelic dyspla-
sias compared with MFS. We therefore propose that the aberrant
TGFβ signalling observed in each of the fibrillin-1-associated dis-
eases is due to different causes. In MFS, we suggest that it is due
to a loss of structural integrity in the fibrillin matrix, which af-
fects TGFβ activation through a change in themechanical proper-
ties of tissues. In contrast, the primary defect in SSS and the
acromelic dysplasias ismore likely to be defective cell-surface in-
teractions with microfibrils rather than a defect in microfibril as-
sembly or stability. The TGFβ dysregulation, fibrosis and dermal
accumulation of microfibril aggregates observed in SSS and the
acromelic dysplasias would then be a secondary response to an
altered signalling program initiated by changes in the surface in-
teractions with microfibrils. Further molecular and cellular stud-
ieswill be required to investigate differences in cellular signalling
in the different disorders.
Materials and Methods
Plasmid construction, mutagenesis and transfection
Construction of the plasmid pcDNA-GFP-Fbn has been described
previously (36). Plasmids for the expression of the NterPro-
cbEGF18-26 constructs were created by amplifying the DNA en-
coding residues T1321 to N1848 as a SalI fragment from a fibril-
lin-1 cDNA clone and inserting this into the XhoI site of the
plasmid pKG52(polyA) (32), which encodes the N-terminal region
of fibrillin-1 up to the proline-rich domain (residues 1–446) under
the control of a thymidine kinase promoter. Mutant constructs
were created using by an overlapping PCR method (41) or the
QuikChange Lightning mutagenesis kit (Agilent).
Transfections were carried out using Lipofectamine 2000 (Life
Technologies) according to the manufacturer’s instructions.
Pools of stable, puromycin-resistant cell lines expressing Nter-
Pro-cbEGF18-26 constructs were created using MSU-1.1 fibro-
blasts (typically >80 clones per pool) as described previously
(32,36,54). Pooling of clones was used to average out the effects
of variations in expression levels between individual clones re-
sulting from random genomic integration and to overcome the
low transient transfection efficiency of fibroblasts. Transfections
of HEK293T cells with GFP-Fbn constructs were carried out in six-
well plates as described previously (36).
Microfibril incorporation assay
Microfibril incorporation assays were carried out as described
previously (36). Briefly, HEK293T cells grown in six-well plates
were transfected with GFP-Fbn constructs using Lipofectamine
2000. Twenty-four hours after transfection, cells were trypsinised
and counted. Co-cultures were established containing 7.5 × 104
FS2 dermal fibroblasts (15) and 7.5 × 104 transfected HEK293T
cells per well of an eight-well Lab Tek II chambered slide, in
400 μl Dulbecco’s modified Eagle medium supplemented with
2 m glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin and
10% (v/v) foetal bovine serum (complete DMEM). After 5 days in
culture, cells were fixedwith 4% (w/v) paraformaldehyde in phos-
phate-buffered saline and stained using a rabbit polyclonal
antibody raised against the fibrillin-1 proline-rich region (32)
and chicken polyclonal anti-GFP (Abcam; ab13970) without
permeabilisation. Goat anti-chicken Alexa488 and goat anti-rab-
bit Alexa568 (Invitrogen) were used for detection. Images were
collected using a Zeiss Axioplan 2 microscope with AxioVision
Rel. 4.8 software.
Immunoblotting
Cells remaining from theHEK293T transfectionswere transferred
to 25-cm2 tissue culture flasks (Greiner) and grown for a further 3
days in complete DMEM to produce cell andmedium samples for
analysis by western blotting. Conditioned media and cell sam-
ples were analysed by immunoblotting as described previously
(32,33), using a chicken anti-GFP antibody followed by a goat
anti-chicken HRP conjugate and enhanced chemiluminescent
detection (Amersham).
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Supplementary Material is available at HMG online.
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